Telix Pharmaceuticals Limited logo

Telix Pharmaceuticals Limited

TLX | NASDAQ
Chart Builder DCF Calculator
$11.98
+$0.67 (+5.92%)
Sep 22, 2026, 2:02 PM ET · Market open

Market Data

Market Cap
$3.83B
Enterprise Value
$6.01B
Beta
0.60
Average Volume
153.87K
Shares Outstanding (Diluted)
356.89M
Shares Change YoY
1.75%
Institutional Ownership
0.76%
Exchange
NASDAQ
ISIN
US87961M1053

Price Performance

Price Change 1M
-1.3%
Price Change 3M
10.8%
Price Change 6M
27.1%
Price Change YTD
48.4%
Price Change 1Y
12.5%
Price Change 3Y
-23.8%
Price Change 5Y
-23.8%
1M CAGR (ann.)
-1.8%
1Y CAGR (ann.)
23.5%
5Y CAGR (ann.)
N/A
All-Time CAGR
-14.6%

Valuation

PE Ratio
119.12
Forward PE
796.71
PEG Ratio
-0.43
Forward PEG
-1.45
PS Ratio
4.31
Forward PS
3.30
PB Ratio
7.87
P/FCF Ratio
-65.16
P/Adj. FCF Ratio
-65.16
P/OCF Ratio
-277.94
EV/Sales
4.58
EV/EBIT
-677.41
EV/EBITDA
130.06
EV/FCF
-69.33
Earnings Yield
0.9%
FCF Yield
-1.6%
Adj. FCF Yield
-1.6%

Financial Health

Net Debt
A$387.42M
Total Debt
A$837.03M
Cash & Short-Term Investments
A$363.63M
Total Assets
A$1.97B
Current Ratio
2.01
Quick Ratio
1.85
Debt / Equity Ratio
1.19
Debt / EBITDA
18.11
Debt / FCF
-9.65
OCF / Debt
-0.02
Interest Coverage
-0.51
Altman Z-Score
3.39
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
52.2%
Operating Profit Margin
-0.8%
EBITDA Margin
3.5%
Net Profit Margin
3.6%
FCF Margin
-6.6%
Adj. FCF Margin
-6.6%
SBC / Revenue
0.0%
SBC Impact (per share)
N/A

Returns

Return on Assets
2.4%
Return on Equity
7.1%
Return on Invested Capital
-0.6%
Return on Capital Employed
-0.6%
Return on Tangible Assets
4.2%

Historical Growth (CAGR)

Revenue CAGR 3Y
637.2%
Revenue CAGR 5Y
85.2%
Revenue CAGR 10Y
43.9%
EPS CAGR 3Y
486.8%
EPS CAGR 5Y
66.0%
EPS CAGR 10Y
4.6%
FCF CAGR 3Y
7.8%
FCF CAGR 5Y
-24.1%
FCF CAGR 10Y
-14.6%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
5
EPS Growth Next 3Y
54.9%
Revenue Growth Next 3Y
16.5%
Earnings Date
Feb 18, 2027
EPS Estimate (next Q)
-$0.02
EPS Growth Est (next Q)
83.2%
Revenue Est (next Q)
$351.08M
Revenue Growth Est (next Q)
19.6%

Fair Value Estimates

Graham Number
$1.77
Graham Upside
-84.3%
Lynch Fair Value
$2.37
Lynch Upside
-79.0%
Price Target
$18
Price Target Upside
59.2%

Cash Flow

Operating Cash Flow
A$-19.19M
Free Cash Flow
A$-86.7M
Adj. Free Cash Flow
A$-86.7M
FCF Per Share
-$0.26
OCF Per Share
-$0.06
OCF/S Ratio
-1.6%

Income Statement

Revenue
A$1.31B
Gross Profit
A$684.05M
Operating Income
A$-10.09M
EBITDA
A$46.22M
Net Income
A$48.26M
EPS (Diluted)
$0.14
Revenue / Employee
$1.14M
Profit / Employee
$41.89K
Employees
1,152

© 2026 bestshares.com. All rights reserved.